

ALK and ROS1 in NSCLC: Optimising the continuum of care

12.00-13.00
Friday 5 May 2017
Room A, Palexpo
Geneva, Switzerland

Light refreshments will be served prior to the symposium

Chair's welcome

Dear Colleague,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium 'ALK and ROS1 in NSCLC: Optimising the continuum of care'. The symposium will be held on **Friday 5 May 2017** from **12.00-13.00**, during the 7th European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

The rapid development of crizotinib and other ALK tyrosine kinase inhibitors (TKIs) allows patients with advanced ALK+ non-small cell lung cancer (NSCLC) to benefit from a continuum of care with sequential ALK-targeted therapies. Furthermore, FDA and EMA approval of crizotinib for advanced ROS1+ NSCLC allows even more patients to benefit from targeted treatment.

During our symposium, the faculty will discuss the benefits of fast, quality-assured molecular testing in NSCLC. We will review the latest clinical outcomes that can be achieved for patients with advanced ALK+ or ROS1+ NSCLC and discuss strategies for maximising these outcomes, illustrated by real-world examples. We will also consider the spectrum of known mechanisms of resistance to crizotinib and other ALK TKIs, and the clinical challenges of resistance in this setting.

I look forward to welcoming you to Geneva and I hope you will join us for what promises to be a highly engaging symposium.

Best regards,



Jean-Charles Soria, Chair
Gustave-Roussy Cancer Center
Paris, France

Programme

- 12.00 Welcome and introduction**
Optimising the continuum of care for patients with oncogenic driven NSCLC
Jean-Charles Soria, Chair (France)
- 12.15 ALK+ NSCLC: How can we maximise the clinical outcome today?**
Nicolas Girard (France)
- 12.35 ROS1+ NSCLC: Clinical data and experience**
Federico Cappuzzo (Italy)
- 12.50 Panel discussion**
All faculty
- 13.00 Meeting close**



Merck KGaA, Darmstadt, Germany, and Pfizer co-promote XALKORI (crizotinib) in the United States, Argentina, Canada, Japan, China, Turkey, and five European Union countries (France, Germany, Italy, Spain, and the United Kingdom). This meeting is organised and funded by Pfizer Oncology
© Pfizer Pharma GmbH. All rights reserved. March 2017. PP-XLK-EUR-0307